ADVANCED DRUG DELIVERY SYSTEMS TO CROSS
$27 BILLION BY 2005
The concept of advanced drug delivery systems
continues to have great appeal. The systems give the product
differentiation and the brand name identity that enable the U.S.
pharmaceutical industry to maintain higher profit margins. Developments
continue at a rapid pace, especially in the area of alternatives to
injected macromolecules, as drug formulators seek to cash in on the $8
billion worldwide market for genetically engineered protein drugs, with
inexpensive but efficacious delivery systems. Advanced technologies also
offer formulators a value-added means of delivering drugs slated for a
lapse in patent protection and a competitive advantage against generic
versions.
According to a soon-to-be-released study from Business
Communications Co., Inc. (www.bccresearch.com)
RC-050U Advanced Drug Delivery Systems: New Developments, New
Technologies, , the U.S. market for the systems is estimated at
$16.3 billion in 2000. Despite the complaints of health care being too
expensive, the U.S. pharmaceutical industry is expected to offer
increasing opportunities for advanced drug delivery systems. The efficacy,
safety, and convenience of the technologies should help sustain an AAGR
(average annual growth rate) of 10.9% over the next five years, when sales
are predicted to be about $27.4 billion.
Estimated at $13.8 billion in 2000, controlled
release (CR) technologies (microencapsulation, polymer/membrane, and
coatings) dominate the market for advanced drug delivery systems. The
intense competition in generic products is resulting in stimulated growth
(7.4%), especially in oral formats, both osmotic and microencapsulated.
The widespread interest in CR systems should result in sales reaching
$19.6 billion by 2005.
Site-selective systems (liposomes, implants,
monoclonal antibodies and intrauterine devices) currently estimated at
$2.2 billion, remain a primary focus of many researchers and one that is
now beginning to reap great financial benefits. Having stood at the brink
of great commercial success for the last decade, the innovative systems
could approach or even outstrip CR sales over the next ten years, with
sales more than tripling by 2005 (a projected $7.4 billion). The ability
to target precise sites for drug delivery is causing in sales to rise at
an AAGR 26.5%.
Sales of transmucosal drug delivery systems that
provide rapid onset of action via direct application of a medication to
the mucosal membranes have also begun to make a noticeable rise, with the
U.S. market estimated at $179 million in 2000. The introduction of inhaled
insulin is expected to play a significant role in boosting sales (a
predicted $335 million), sustaining an AAGR of 13.3% for the five-year
period.
Advanced drug delivery systems, through
2005
($ Millions)
|
System
|
2000
|
2005
|
AAGR%
2000-2005
|
|
Controlled release
|
13,811
|
19,595
|
7.2
|
|
Site-selective
|
2,292
|
7,422
|
26.5
|
|
Transmucosal
|
179
|
335
|
13.4
|
|
Total
|
16,282
|
27,352
|
10.9
|
Advanced drug delivery systems, through 2005
RC-050U Advanced Drug Delivery
Systems: New Developments, New Technologies
Published: January 2001
Data and analysis provided courtesy of
BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT
06855, Telephone: (203) 853-4266; ext. 309, Email: publisher@bccresearch.com |
